Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 1
1980 1
1990 2
1992 1
1995 2
1996 1
1998 1
1999 1
2005 1
2009 1
2013 2
2014 3
2015 1
2016 2
2017 4
2018 5
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Perkovic V, et al. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. N Engl J Med. 2024. PMID: 38785209 Clinical Trial.
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, Ross L, Liu Y, Burns CE, Abbasi SA, Pannacciulli N; MariTide Phase 2 Obesity Trial Investigators. Jastreboff AM, et al. N Engl J Med. 2025 Sep 4;393(9):843-857. doi: 10.1056/NEJMoa2504214. Epub 2025 Jun 23. N Engl J Med. 2025. PMID: 40549887 Clinical Trial.
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
Rossing P, Bakris G, Perkovic V, Pratley R, Tuttle KR, Mahaffey KW, Idorn T, Belmar N, Bosch-Traberg H, Rasmussen S, Busch RS, Schmieder RE, Gillard P, Mann JFE; FLOW Investigator Group. Rossing P, et al. Diabetes Care. 2025 Nov 1;48(11):1878-1887. doi: 10.2337/dc25-0472. Diabetes Care. 2025. PMID: 40730031 Free PMC article. Clinical Trial.
[Anti-insulin receptor antibody].
Wasada T, Hasumi S. Wasada T, et al. Among authors: hasumi s. Nihon Rinsho. 1999 Dec;57 Suppl:364-7. Nihon Rinsho. 1999. PMID: 10778140 Review. Japanese. No abstract available.
[Insulin receptor antibodies].
Wasada T, Hasumi S. Wasada T, et al. Among authors: hasumi s. Nihon Rinsho. 2005 Aug;63 Suppl 8:536-9. Nihon Rinsho. 2005. PMID: 16149571 Review. Japanese. No abstract available.
Four new Amaryllidaceae alkaloids from Zephyranthes candida.
Shitara N, Hirasawa Y, Hasumi S, Sasaki T, Matsumoto M, Wong CP, Kaneda T, Asakawa Y, Morita H. Shitara N, et al. Among authors: hasumi s. J Nat Med. 2014 Jul;68(3):610-4. doi: 10.1007/s11418-014-0819-y. Epub 2014 Feb 14. J Nat Med. 2014. PMID: 24526460
Digoxin degradation in acidic dissolution medium.
Sonobe T, Hasumi S, Yoshino T, Kobayashi Y, Kawata H, Nagai T. Sonobe T, et al. Among authors: hasumi s. J Pharm Sci. 1980 Apr;69(4):410-3. doi: 10.1002/jps.2600690412. J Pharm Sci. 1980. PMID: 7373535
26 results